Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alana M Ciolek"'
Autor:
Yuming Ning, Yuji Kaku, Alana M Ciolek, Paul Kurlansky, Daniel Brodie, Nir Uriel, A. Melehy, Koji Takeda, Justin Fried, Gabriel Sayer, Yoshifumi Naka, Jonathan Hastie, Hiroo Takayama, Andrew Eisenberger
Publikováno v:
The Annals of Thoracic Surgery. 113:131-137
Background Anticoagulation therapy management during venoarterial extracorporeal membrane oxygenation (ECMO) is particularly difficult in postcardiotomy shock patients given a significant bleeding risk. We sought to determine the effect of anticoagul
Autor:
Donald C Moore, Kathryn Dane, Alana M Ciolek, Surabhi Palkimas, Justin Arnall, Julie Der-Nigoghossian
Publikováno v:
Annals of Pharmacotherapy. 56:831-838
Objective: To review the pharmacology, dosing and administration, safety, clinical efficacy, and role of eptacog beta in the treatment of congenital hemophilia with inhibitors. Data Sources: A literature search of PubMed (1966 to August 2021) was con
Autor:
Caroline Der-Nigoghossian, Michelle Gunther, Trisha Pedone, Hetal B. May, Amy L. Dzierba, Audrey J. Littlefield, Corey Witenko, Viha D. Patel, Brittany S. Verkerk, Liz G. Ramos, Jenny Shah, Mona Patel, Teresa Poon, Alana M Ciolek, Karen Berger, Peter Nikolos, Monica Mehta, Taylor Chuich, Justin Muir
Publikováno v:
Journal of the American College of Clinical Pharmacy
Beginning in March 2020, New York City began the fight against coronavirus disease 2019. Health care workers were faced with a disease that led to significant morbidity and mortality with no proven therapies. As hospitals became inundated with patien
Autor:
Audrey J Littlefield, Gregory Jones, Alana M. Ciolek, Melana Yuzefpolskaya, Douglas L. Jennings
Publikováno v:
Heart Failure Reviews. 26:277-288
Advancements in the design and functionality of continuous flow left ventricular assist devices (CF-LVADs), as well as a limited number of donor hearts, have resulted in an increased utilization of this therapy among advanced heart failure (HF) patie
Autor:
Veli K. Topkara, Dylan P. Marshall, Rashmi Jain, Lauren K. Truby, Audrey J Littlefield, Douglas L. Jennings, Alana M Ciolek
Publikováno v:
The International journal of artificial organs. 44(12)
Introduction: Gastrointestinal bleeding (GIB) remains a common and vexing complication of left ventricular assist device (LVAD) support. Recent single-center analyses suggest that ACE inhibitors (ACEi)/angiotensin receptor blockers (ARB) and digoxin
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 24:186-191
Thrombate III is a human plasma-derived antithrombin III (AT-III) often utilized in patients on extracorporeal membrane oxygenation (ECMO) with suspected AT-III-mediated heparin resistance. It is supplied as 500-U and 1000-U vials, costing US$4.66 pe
Publikováno v:
Diabetes. 68
Basal-bolus insulin (BBI) therapy is recommended for treatment of hyperglycemia in the inpatient setting, but many patients still receive sliding scale insulin (SSI) that has been shown to be less effective. To evaluate the transition from insulin dr
Publikováno v:
The Annals of pharmacotherapy. 53(4)
Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-relate
Publikováno v:
Artificial Organs. 44:339-340
Publikováno v:
The Journal of Heart and Lung Transplantation. 38:S307
Purpose In patients undergoing percutaneous coronary intervention (PCI) complicated by cardiogenic shock, venoarterial extracorporeal membrane oxygenation (VA-ECMO) is used as a bridge to surgery, ventricular assist device (VAD), or recovery. Bleedin